Risks
3 risks
Risk Intelligence
Cenexi turnaround delay
View Risks →Gland Pharma Limited — Q2 FY26
Gland Pharma reported a strong Q2 FY26 with consolidated revenue of INR 14,869 million, up 6% YoY, and EBITDA of INR 3,139 million (21% margin).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma reported a strong Q2 FY26 with consolidated revenue of INR 14,869 million, up 6% YoY, and EBITDA of INR 3,139 million (21% margin). Base business EBITDA margin improved to 37% (adjusted), driven by favorable product mix and cost initiatives. U.S. revenue grew 8% YoY to INR 8,005 million, supported by new launches (7 molecules) and volume growth. Cenexi revenue rose 21% YoY in INR terms, though EBITDA remained negative due to a planned shutdown; management expects Cenexi to break even in Q3. Key growth drivers include the upcoming launch of dalbavancin, GLP-1 capacity expansion (40M to 140M cartridges), and biologic CDMO ramp-up. Management maintained mid-teens consolidated revenue growth guidance for FY26. Risk: Cenexi turnaround may be delayed if revenue ramp-up falls short of EUR 50 million quarterly target.
ग्लैंड फार्मा ने दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,486.9 करोड़ रुपये रही, जो पिछले साल से 6% ज्यादा है। कमाई पर खर्च घटाने के बाद बचा मुनाफा (EBITDA) 313.9 करोड़ रुपये (21% मार्जिन) रहा। अमेरिका में बिक्री 8% बढ़कर 800.5 करोड़ रुपये हुई, जिसमें 7 नई दवाओं की लॉन्चिंग से मदद मिली। यूरोपीय कंपनी सेनेक्सी की कमाई 21% बढ़ी, लेकिन प्लांट बंद होने से घाटा हुआ; उम्मीद है कि अगली तिमाही में यह बराबर आ जाएगी। आने वाले समय में नई दवा डाल्बावैंसिन, GLP-1 क्षमता बढ़ाने और बायोलॉजिक दवा बनाने से कमाई बढ़ेगी। कंपनी ने पूरे साल 15% कमाई बढ़ोतरी का लक्ष्य रखा है। जोखिम: अगर सेनेक्सी की तिमाही कमाई 50 करोड़ यूरो से कम रही तो उसका सुधार देर हो सकता है।
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
U.S. Revenue Growth (YoY)
8%
+8% YoY
U.S. revenue grew 8% YoY to INR 8,005 million in Q2, driven by new launches and volume growth.
Cenexi Revenue Growth (YoY, INR)
21%
+21% YoY
Cenexi revenue increased 21% YoY to INR 4,102 million in Q2, supported by strong site performance.
Base Business Adjusted EBITDA Margin
37%
+200bps YoY
Base business adjusted EBITDA margin improved to 37% in Q2, exceeding the 35% target.
Cartridge Fill-Finish Capacity Expansion
140M units
+100M units
Gland plans to expand cartridge fill-finish capacity from 40M to 140M units to support GLP-1 and insulin programs.
What Changed vs Last Quarter
NEW
Cenexi EBITDA improvement year-on-year
Cenexi EBITDA losses reduced to EUR 5 million in H1 from EUR 11 million last year; management expects continued improvement.
NEW
CapEx of INR 2,500M for base business in FY26
Expected CapEx for Gland base business is approximately INR 2,500 million for FY26, focused on capacity expansion.
UPDATED
Mid-teens consolidated revenue growth for FY26
Management reaffirmed mid-teens revenue growth guidance for FY26, driven by new launches (dalbavancin, colistimethate) and Cenexi improvement.
UPDATED
Cenexi break-even in Q3 FY26
Cenexi is expected to break even in Q3 FY26, supported by EUR 50 million quarterly revenue target and cost initiatives.
DROPPED
GLP-1 cartridge capacity expansion to 140M by Mar'26
The new 100 million cartridge line will be ready for commercialization by March 2026, adding to the existing 40 million capacity.
DROPPED
20 million GLP-1 units commercialization in FY27
Management expects to commercialize around 20 million pens/cartridges in FY27, primarily for RoW markets.
NEW RISK
Cenexi turnaround delay
Cenexi's break-even depends on achieving EUR 50 million quarterly revenue; any shortfall could delay profitability.
NEW RISK
ROW business growth lumpiness
ROW revenue was flat due to a 53% decline in tech transfer/CMO revenue, though product sales grew 19%; recovery may take a few quarters.
RISK GONE
Cenexi Q2 dip due to summer shutdown
Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround trajectory.
RISK GONE
U.S. tariff uncertainty on pharmaceuticals
An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.
RISK GONE
GLP-1 capacity utilization ramp-up slower than expected
Management indicated that the new 100 million cartridge line will not see significant utilization until FY29-30, as most markets open later. Near-term revenue contribution may be limited.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q1 FY26, Q2 FY25, Q4 FY25
Management expects Cenexi to deliver positive EBITDA in Q3 FY26, with Q2 being lower due to summer shutdown.
Mentioned in Q2 FY25, Q3 FY25
Collaboration with Dr. Reddy's for biologics CDMO is expected to generate incremental revenue starting next financial year (FY26).
Mentioned in Q1 FY26, Q4 FY25
The new 100 million cartridge line will be ready for commercialization by March 2026, adding to the existing 40 million capacity.
Mentioned in Q1 FY26, Q3 FY25
An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.
Fast read
Guidance and risk preview
Management reaffirmed mid-teens revenue growth guidance for FY26, driven by new launches (dalbavancin, colistimethate) and Cenexi improvement.
Cenexi's break-even depends on achieving EUR 50 million quarterly revenue; any shortfall could delay profitability.
View Risks →